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Based on the growing prevalence of myopia around theworld, in particular in the young generations in East and
Southeast Asia, it was the vision of the late Professor Brien
Holden to initiate the International Myopia Institute. For long,
Professor Holden, who already had founded and led the Brien
Holden Vision Institute in Sydney, had realized the need to
address the issues of myopia and myopia-related risks to vision,
how clinicians could best manage myopia, and how further
myopia research could be advanced. Myopia needed to be
recognized as a public health issue if there was to be a change
in the approach to this condition, and only a collaborative effort
across all eye care professions and researchers could bring this
about. Under the auspices of the International Myopia Institute,
experts from different myopia-related fields have come
together, so that synergistic effects could develop and to make
their latest research accessible and easy to understand for
practitioners, governments, policy makers, educators, and the
general public. Starting with a World Health Organization
(WHO)–associated global scientific meeting on myopia, which
was held at the Brien Holden Vision Institute in Sydney,
Australia in 2015, subgroups of researchers within The
International Myopia Institute formed to address the major
aspects of myopia. These include the public health issues of
myopia, sequelae of myopia, such as the increased risks of sight-
threatening complications due to glaucoma, retinal detach-
ment, and myopic macular degeneration, the classification of
myopia, prevention of myopia and its complications, and
evidence for treatments. With myopia projected to affect 50%
of the world population by 2050 and the fear that myopia could
become the most common cause of irreversible blindness
worldwide,1 The International Myopia Institute, thus, is a
collaborative effort to bring together individuals from across all
areas of myopia research.
As a first major step, The International Myopia Institute has
edited in this special IOVS issue a series of white papers on
defining and classifying myopia, potential interventions,
clinical trials and instrumentation, industry guidelines and
ethical considerations, clinical management guidelines, exper-
imental models of emmetropization and myopia, and the
genetics of myopia. These articles, summarizing the current
knowledge in the field and showing trends for future
developments, may form a basis for further research, bridging
gaps, and connecting people who so far had not intensively
exchanged information and ideas. The IMI Myopia white paper
reports initiative was chaired by Earl Smith and James
Wolffsohn and facilitated by Monica Jong.
The future initiatives and role of The International Myopia
Institute will be to foster these scientific cooperations, to be a
platform for further harmonization of definitions and guide-
lines, and also to promote the connections between the
scientific world and the public, ultimately supporting the
advocacy of this issue at the level of governments, peak health
and regulating bodies.
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